GSK plc (the 'Company') Vesting of Performance Share Plan Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2021 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards were made in 2021 and the three-year performance period commenced on 1 January 2021 and ended on 31 December 2023. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.

The performance measure vesting details for those PDMRs who received awards in 2021 are set out in the following table.

		Outcome ar Lev	•
Portion of the Award	Measure and Outcome	% of maximum	% of award
30%	Adjusted Free Cash Flow - For the three years ending 31 December 2023, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £9.81bn, which is above the revised amount of £6.54bn required for maximum vesting. Adjustments to the original target and vesting schedule were set out in detail in the 2022 Annual Report.	100	30.00
30%	Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 9th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.	0	0.00
20%	Innovation Sales - For the three-year period, the Company achieved revenues from new products calculated in accordance with the principles for the measure of £18.651bn, which is slightly below the level of £18.667bn required for 100% vesting. The threshold vesting level was £15.273bn.	99.77	19.95
20%	Pipeline Progress - measure is equally weighted between: - Pivotal trial starts - Major regulatory approvals	100 100	10.00 10.00
	Total vesting for 2021 award Lapsed	69.95 30.05	69.95

The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 9 February 2024. The balance of the award made to each PDMR and PCA has lapsed.

The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting date were £16.60 and \$41.91.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')					
1.						
a)	Name	Er	Emma Walmsley			
b)	Position/status	Cł	nief Executive Of	ficer		
c)	Initial notification/ amendment	Ini	tial notification			
2.	Details of the issuer, auctioneer or auctio			nce market pa	articipant, auction platform,	
a)	Name	GS	SK plc			
b)	LEI	54	93000HZTVUYL	O1D793		
3.	Details of the transa (ii) each type of tran transaction(s) has be	Isad	ction; (iii) each		for (i) each type of instrumer each place where	nt;
a)	Description of the financial instrument		rdinary Shares o IN: GB00BN7SV		ach ('Ordinary Shares')	
b)	Nature of the transaction	un		y's 2017 Perfor	esting on awards granted in 202 mance Share Plan. These shar d.	
c)	Price(s) and volume(s)		Price(s)	,	Volume(s)	
			£0.00		441,309	
d)	Aggregated information	N/.	A (single transa	ction)		
	Aggregated volume Price					
e)	Date of the transaction	20	024-02-09			
f)	Place of the transaction	N/.	A			

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Diana Conrad			
b)	Position/status	Chief People Officer			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor			
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan			

c)	Price(s) and volume(s)	Price(s) Volume(s) £0.00 89.414
		20.00 09,414
d)	Aggregated information	WA (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Diana	I Conrad		
b)	Position/status	Chief	People Officer		
c)	Initial notification/ amendment	Initial	notification		
2.	Details of the issuer, auctioneer or auctio			market pa	articipant, auction platform,
a)	Name	GSK	plc		
b)	LEI	54930	000HZTVUYLO1D	0793	
3.	Details of the transac (ii) each type of trans transaction(s) has be	sactio	n; (iii) each dat	repeated e; and (iv)	for (i) each type of instrument; each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	award			eet tax liabilities for the vesting of ne Company's 2017 Performance
c)	Price(s) and volume(s)	Pri	ice(s)		Volume(s)
		£1(6.6055		47,864
d)	Aggregated information	N/A (s	single transaction)	
	Aggregated volume Price				
e)	Date of the transaction	2024-	02-09		
f)	Place of the transaction	Londo	on Stock Exchanç	ge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	James Ford			
b)	Position/status	SVP and Group General Counsel, Legal and Compliance			

c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auctio	/ r, emission allowance market participant, auction platform, on monitor			
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D	793		
3.		saction; (iii) each dat	repeated for (i) each type of instrumer e; and (iv) each place where		
a)	Description of the financial instrument	Ordinary shares of 31 1 ISIN: GB00BN7SWP6	¼ pence each ('Ordinary Shares') 3		
b)	Nature of the transaction		/ Shares vesting on awards granted in 202 2017 Performance Share Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		£0.00	139,077		
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	2024-02-09			
f)	Place of the transaction	N/A			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	James Ford		
b)	Position/status	SVP and Group General C	Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793	3	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63	ence each ('Ordinary Shares')	
b)	Nature of the transaction		es to meet tax liabilities for the vesting ounder the Company's 2017 Performanc	
c)	Price(s) and volume(s)	Price(s) £16.6055	Volume(s)	
		£ 10.000	65,367	
\لہ	Annantad	NI/A (cincle transaction)		

1	a)	Aggregated information	IWA (single transaction)
		Aggregated volume Price	
1	e)	Date of the transaction	2024-02-09
1	f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Sally Jackson			
b)	Position/status	SVP, Global Comm	unications and CEO Office		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auction		ce market participant, auction platform,		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLC	1D793		
3.	(ii) each type of tran	the transaction(s): section to be repeated for (i) each type of instrument; rpe of transaction; (iii) each date; and (iv) each place where n(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of ISIN: GB00BN7SW	81 ¼ pence each ('Ordinary Shares') P63		
b)	Nature of the transaction	The number of Ordin under the Company	nary Shares vesting on awards granted in 2021 's 2017 Performance Share Plan		
c)	Price(s) and volume(s	Price(s) £0.00	Volume(s) 52,746		
d)	Aggregated information	N/A (single transac	ion)		
	Aggregated volume Price				
e)	Date of the transaction	2024-02-09			
f)	Place of the transaction	N/A			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Sally Jackson		
b)	Position/status	SVP, Global Communications and CEO Office		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		

ĺ							
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan					
c)	Price(s) and volume(s))	Price(s) £16.6055	Volume(s) 24,791			
d)	Aggregated information Aggregated volume Price	N/	A (single transaction)				
e)	Date of the transaction	20	24-02-09				
f)	Place of the transaction	Lc	ndon Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Dylan Jackson		
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio		nce market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYL	01D793	
3.	(ii) each type of tran	the transaction(s): section to be repeated for (i) each type of instrument; pe of transaction; (iii) each date; and (iv) each place where n(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of ISIN: GB00BN7SV	31 ¼ pence each ('Ordinary Shares') VP63	
b)	Nature of the transaction	The number of Orc 2022 and 2023 un	inary Shares vesting on awards granted in 2021 der the Company's 2017 Performance Share Pla	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£0.00	7,642	
d)	Aggregated information	N/A (single transa	ction)	
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')						
			-				
a)	Name	Dy	Dylan Jackson				
b)	Position/status		PCA of Ms S Jackson (SVP, Global Communications and CEO Office)				
c)	Initial notification/ amendment	Ini	Initial notification				
2.	Details of the issuer, auctioneer or auctio		nission allowance market pa nonitor	rticipant, auction platform,			
a)	Name	GS	SK plc				
b)	LEI	54	5493000HZTVUYLO1D793				
3.		Isad	ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where sen conducted				
a)	Description of the financial instrument		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan					
c)	Price(s) and volume(s))	Price(s)	Volume(s)			
			£16.6055	3,592			
d)	Aggregated information	N/A (single transaction)					
	Aggregated volume Price						
e)	Date of the transaction	2024-02-09					
f)	Place of the transaction	Lo	ndon Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Luke Miels			
b)	Position/status	Chief Commercial Officer			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GSK plc			
b)	LEI 5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the	The number of Ordinary Shares vesting on awards granted in 2021			

		transaction	under the Company's 2017 Penormance Share Plan
-	c)	Price(s) and volume(s)	Price(s) Volume(s) £0.00 195,810
	d)	Aggregated information Aggregated volume Price	N/A (single transaction)
	e)	Date of the transaction	2024-02-09
-	f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Luke Miels		
b)	Position/status	Chief Commercial (Officer	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		ce market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYL0	01D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of ISIN: GB00BN7SW	31 ¼ pence each ('Ordinary Shares') P63	
b)	Nature of the transaction		y Shares to meet tax liabilities for the vesting of 2021 under the Company's 2017 Performance	
c)	Price(s) and volume(s) Price(s)	Volume(s)	
		£16.6055	13,864	
d)	Aggregated information	N/A (single transac	tion)	
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	London Stock Excl	ange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Shobie Ramakrishnan		
b)	Position/status Chief Digital and Technology Officer			
2)	Initial natification/	Initial patification		

C)	initial notification/ amendment	initial nothication			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where een conducted			
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044			
b)	Nature of the transaction	The number of ADSs vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan			
c)	Price(s) and volume(s)	Price(s) \$0.00	Volume(s) 5,383		
d)	Aggregated information Aggregated volume Price	N/A (single transaction)			
e)	Date of the	2024-02-09			
	transaction				
f)	Place of the transaction	N/A			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Shobie Ramakrishnan		
b)	Position/status	Chief Digital and Techno	logy Officer	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		narket participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D7	93	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	American Depositary Sh ISIN: US37733W2044	ares ('ADSs')	
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan		
c)	Price(s) and volume(s) Price(s)	Volume(s)	
		\$41.84	2,894	
			I	

	Aggregated volume Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	David Redfern			
b)	Position/status	President, Corpo	President, Corporate Development		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auctio		ance market participar	nt, auction platform,	
a)	Name	GSK plc			
b)	LEI	5493000HZTVUY	LO1D793		
3.	(ii) each type of tran	transaction(s): section to be repeated for (i) each type of instrument; of transaction; (iii) each date; and (iv) each place where has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction		dinary Shares vesting on ny's 2017 Performance S	awards granted in 2021 Share Plan	
C)	Price(s) and volume(s)	Price(s)	Volume	(s)	
		£0.00	161,385	5	
d)	Aggregated information	N/A (single trans	action)		
	Aggregated volume Price				
e)	Date of the transaction	2024-02-09			
f)	Place of the transaction	N/A			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name David Redfern			
b)	Position/status	President, Corporate Development		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan			
c)	Price(s) and volume(s))	Price(s) £16.6055	Volume(s) 75,851	
d)	Aggregated information Aggregated volume Price	NA (single transaction)			
e)	Date of the transaction	20	24-02-09		
f)	Place of the transaction	Lc	ndon Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Regis Simard		
b)	Position/status	President, Global Supply Chain		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio		market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1E	1793	
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	The number of Ordinar under the Company's 2	y Shares vesting on awards granted in 2021 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s) £0.00	Volume(s) 133,024	
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Regis Simard		
b)	Position/status	President, Global Supply	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		narket participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D7	93	
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where een conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction		ares to meet tax liabilities for the vesting of under the Company's 2017 Performance	
c)	Price(s) and volume(s) Price(s)	Volume(s)	
		£16.6055	62,522	
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	London Stock Exchange	e (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Phil Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, on monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	

		· · · · · · · · · · · · · · · · · · ·		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£0.00	73,728	
d)	Aggregated information	N/A (single transactio	on)	
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Phil Thomson		
b)	Position/status	President, Global Affairs		
c)	Initial notification/ amendment	Initial notificat	tion	
2.	Details of the issuer, auctioneer or auctio		lowance ma	rket participant, auction platform,
a)	Name	GSK plc		
b)	LEI	5493000HZT\	/UYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction			es to meet tax liabilities for the vesting of inder the Company's 2017 Performance
c)	Price(s) and volume(s)	Price(s)		Volume(s)
		£16.6055		34,653
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	London Stock	< Exchange ()	ALON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health	
c)	Initial notification/ amendment	Initial notification	

2.	Details of the issuer, auctioneer or auctio	the issuer, emission allowance market participant, auction platform, r or auction monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1[0793	
3.	(ii) each type of trans	he transaction(s): section to be repeated for (i) each type of instrument; be of transaction; (iii) each date; and (iv) each place where (s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan		
c)	Price(s) and volume(s)	Price(s) £0.00	Volume(s) 94,120	
d)	Aggregated information Aggregated volume Price	N/A (single transaction)		
e)	Date of the transaction	2024-02-09		
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		rket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	i -
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	44,237
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		

	FIICE	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Tony Wood	
b)	Position/status	Chief Scientific Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1[0793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction		y Shares vesting on awards granted in 2021 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	24,473
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/p	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Tony Wood		
b)	Position/status	Chief Scientific Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			

a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s) £16.6055	Volume(s) 11,503
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Victoria Whyte				
b)	Position/status	Company Secretary				
C)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio	emission allowance market participant, auction platform, n monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	(ii) each type of tran	transaction(s): section to be repeated for (i) each type of instrument; of transaction; (iii) each date; and (iv) each place where has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	Price(s) £0.00	Volume(s) 9,456			
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume Price					
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

	1.	Details of PDMR/per	Details of PDMR/person closely associated with them ('PCA')		
ſ	a)	Name	Victoria Whyte		

b)	Position/status	Company Secretary					
c)	Initial notification/ amendment	Initial notification					
2.		etails of the issuer, emission allowance market participant, auction platform, actioneer or auction monitor					
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan					
c)	Price(s) and volume(s)		Price(s)	Volume(s)			
			£16.6055	4,445			
d) Aggregated N/A (single tran information		A (single transaction)					
	Aggregated volume Price						
e)	Date of the transaction	20	24-02-09				
f)	Place of the transaction	London Stock Exchange (XLON)					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHSFWFIDELSEEE